Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

NCT03543813 is registered in ClinicalTrials.gov with CytomX Therapeutics as lead sponsor.

NCT NCT03543813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03543813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)
Lead sponsor
CytomX Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
June 15, 2018
Completion date
June 1, 2023
Enrollment
133 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, esophageal cancer, head and neck cancer, non small cell lung cancer, solid tumor, adult